Last Updated: November 22, 2026 Reading Time: 8 min
Some 2027 FEHB plans charge 50% coinsurance for weight-loss GLP-1 drugs, and the drug makers now sell Wegovy and Zepbound directly for cash. Whether the Wegovy cash price or your FEHB plan costs less depends on a number that is not public. Here is the comparison for four plan options whose 2027 brochures we read, the math to run for your own plan, and what you give up when you pay cash.
Estimated monthly cost in 2027, plan against cash
| Drug and plan option | Plan rule in the 2027 brochure | Estimated plan cost a month | Cash price a month (as of Nov. 22, 2026) |
|---|---|---|---|
| Wegovy, GEHA High | 50% coinsurance for anti-obesity GLP-1 drugs | $337.50 | $349 |
| Wegovy, GEHA Standard | 40% up to $350 (preferred) or 60% up to $550 (non-preferred) | $270.00 or $405.00 | $349 |
| Wegovy, FEP Blue Standard | 30% (Tier 2) or 50% (Tier 3) | $202.50 or $337.50 | $349 |
| Wegovy, FEP Blue Basic | 35% up to $175 (Tier 2) or 60% (Tier 3) | $175.00 or $405.00 | $349 |
| Zepbound 7.5 to 15 mg KwikPen, GEHA High | 50% coinsurance for anti-obesity GLP-1 drugs | $543.50 | $449 with a refill every 45 days, otherwise $499 to $699 |
Plan costs are FedTools estimates, not plan quotes. We applied each brochure's rate to the list price: $675 a month for Wegovy from January 1, 2027, and $1,087 for Zepbound. Your plan's real base price, called the plan allowance, is not public and can differ from list. Where we show two figures, we could not confirm which tier the drug is on. Plan coverage also needs prior approval. Cash prices are the manufacturers' published self-pay prices for maintenance doses and can change.
Wegovy and Zepbound Cash Price Right Now
These are the manufacturers' own self-pay prices on November 22, 2026.
Wegovy (Novo Nordisk). The pen is $349 a month. New patients pay $199 a month for the two starter doses (0.25 mg and 0.5 mg), for two fills, through December 31, 2026. The Wegovy pill is $149 to $299 a month by dose. The higher-dose Wegovy HD pen is $399.
Novo Nordisk has not published its 2027 self-pay prices. Its page says pricing will be updated after December 31, 2026, and that it can change or cancel the program at any time.
Zepbound (Lilly). The self-pay price is $299 a month for the 2.5 mg dose and $399 for 5 mg. Higher doses are $449 a month if you buy each refill within 45 days. Miss that window and the regular price is $499 for 7.5 mg and $699 for 10 mg and up. The dose-specific prices and refill rule quoted here are for the KwikPen. The retrieved primary text confirms a starting price of $299 for vials, but not their complete dose-specific schedule.
TrumpRx. The site was live on November 22, 2026. It showed lowest prices of $199 a month for the Wegovy pen and $299 for Zepbound. Those match the manufacturers' starting-dose prices. Maintenance doses cost more on the manufacturers' own pages.
FEHB Coinsurance for Four 2027 Plan Options
We read the 2027 brochures for FEP Blue Standard and Basic (RI 71-005) and GEHA High and Standard (RI 71-006).
GEHA High charges 50% coinsurance for anti-obesity GLP-1 drugs in 2027, at network retail and by mail. The brochure says the tiered cost sharing no longer applies to these drugs and states no dollar cap for them.
GEHA Standard lists no separate rate for anti-obesity drugs. Its regular tiers are 40% up to $350 for a preferred drug and 60% up to $550 for a non-preferred drug, for a 30-day supply at a network retail pharmacy. Which tier your drug is on is in GEHA's formulary, which we did not read.
FEP Blue Standard and Basic cover drugs prescribed to treat obesity in 2027, with prior approval. There is no special rate for them. You pay your drug's tier rate at a preferred retail pharmacy:
- Standard: 30% of the plan allowance for Tier 2 and 50% for Tier 3, with no dollar cap on those two tiers.
- Basic: 35% for Tier 2, capped at $175 for a 30-day supply, and 60% for Tier 3 with no cap.
Neither FEP Blue option has a deductible on prescription drugs, so the percentage applies from the first fill of the year. These rates are for members whose Medicare Part B is not primary. The brochure does not name the covered obesity drugs. The formulary does. According to Consumers' Checkbook, FEP Blue Standard and Basic cover Wegovy but not Zepbound in 2027. Confirm that in FEP Blue's 2027 formulary before you rely on it.
Coverage has conditions at both carriers. GEHA requires prior authorization for obesity medications in 2027. It also requires you to take part in its virtual weight-management program, including intensive behavioral therapy, before and during treatment. FEP Blue requires prior approval, and the brochure says it must be renewed periodically.
For other carriers, we did not read the brochures. Consumers' Checkbook reports that most carriers raised the weight-loss GLP-1 cost share to 50% for 2027. Our earlier post on the 50% cost share claim covers that reporting.
The Break-Even Math for Your Plan
For these drug benefits, multiply the plan allowance by your coinsurance rate, then apply any per-fill dollar cap.
For an uncapped coinsurance benefit, break-even plan price = cash price ÷ your coinsurance rate. A per-fill cap can change or eliminate that break-even point.
- Wegovy at 50%: $349 ÷ 0.50 = $698. If your plan's price for Wegovy is above $698 a month, cash costs less per month. Below $698, the plan costs less.
- Zepbound at 50%: $449 ÷ 0.50 = $898.
Now compare with list prices. Wegovy's list price drops to $675 a month on January 1, 2027. Fifty percent of $675 is $337.50, about $12 less than the $349 cash price. Zepbound's list price is $1,087. Fifty percent of that is $543.50, about $95 more than the $449 cash price.
Novo Nordisk says its list-price cut is aimed at people whose share is a percentage of list price, and that it does not change the self-pay price.
To settle it for your own case, open your plan's 2027 drug-cost tool, find the drug and dose, and read the dollar amount. Then compare it with the cash price for the same dose.
What You Give Up When You Pay Cash
The first cost is credit toward your out-of-pocket maximum. Both brochures count the cost sharing you pay for covered services toward the catastrophic maximum. A drug you buy for cash outside the plan is not a claim the plan has processed. The manufacturers' terms point the same way. Novo Nordisk's terms say money spent on the self-pay offer will not count toward your deductible or out-of-pocket requirements and cannot be submitted to your insurer. Lilly's terms have the buyer agree not to seek reimbursement and not to apply the cost toward any deductible or out-of-pocket requirement.
So treat a cash purchase as building no credit toward the maximum. Neither brochure has a sentence that names manufacturer cash programs. That conclusion comes from the "covered services" rule plus the manufacturers' terms.
The 2027 maximums for Self Only, with preferred or in-network providers, are $7,000 (FEP Blue Standard), $8,500 (FEP Blue Basic), $7,500 (GEHA High) and $8,000 (GEHA Standard). If you expect other large medical bills in 2027, plan cost sharing on the drug moves you toward that ceiling. Treat cash as not moving you toward it.
The second is control. Because the self-pay offer operates outside insurance, a cash fill does not go through the plan's prior approval or GEHA's program requirement. It also means the 45-day refill rule on Zepbound is yours to manage, and the price can change when the manufacturer decides.
Can You Use HSA or FSA Money for the Cash Price?
IRS Publication 502 counts amounts you pay for prescribed medicines and drugs as medical expenses. It also says you can't include amounts you pay to lose weight unless the weight loss is a treatment for a specific disease diagnosed by a physician, such as obesity, hypertension or heart disease.
If you have an HSA (in FEHB, that means you are or were in an HSA-qualified high deductible plan), then on that reading HSA money can pay a cash price for prescribed Wegovy or Zepbound when it treats a diagnosed disease such as obesity and insurance did not also pay for it. The IRS publications do not name these drugs. That is our reading of the publications, not an IRS ruling on GLP-1 drugs.
A health care FSA can only reimburse qualified medical expenses. Check the FSAFEDS eligible-expense list for the documentation it asks for before you count on reimbursement.
How to Decide in Four Steps
- Look up your drug and dose in your plan's 2027 drug-cost tool. Write down the monthly dollar amount.
- Look up the manufacturer's cash price for the same dose and form.
- If the two are close, lean toward the plan. Plan cost sharing counts toward the catastrophic maximum, and a cash purchase should be treated as building no credit toward it.
- If cash is clearly lower, check the conditions: the 45-day refill rule for Zepbound, and that Wegovy's 2027 cash price is not yet set.
Open Season ends Monday, December 14, 2026, unless OPM changes the dates. If the drug is a large part of your yearly cost, compare plans before then.
Compare Your FEHB Plan Options
Use our free FEHB Plan Comparison tool to put two plans side by side on premiums and cost sharing for 2027. It does not price individual drugs, so bring the monthly drug figure from your plan's own tool. For the premium side alone, pick a plan and enrollment type in the FEHB Calculator.
Frequently Asked Questions
Is it cheaper to pay cash for Wegovy than to use FEHB in 2027?
It depends on your plan's price for the drug, which is not public. If a plan charges 50% of Wegovy's 2027 list price of $675, that is $337.50 a month, about $12 less than the $349 cash price published on November 22, 2026. Novo Nordisk has not set its 2027 cash price. Check your plan's 2027 drug-cost tool for the real figure.
Does a cash purchase of Wegovy or Zepbound count toward my FEHB out-of-pocket maximum?
Treat it as not counting. The FEP Blue and GEHA 2027 brochures count cost sharing you pay for covered services, and a cash purchase outside the plan is not a plan claim. Novo Nordisk's and Lilly's self-pay terms also say the spending does not count toward a deductible or out-of-pocket requirement and cannot be submitted to an insurer.
What does GEHA charge for weight-loss GLP-1 drugs in 2027?
GEHA High charges 50% coinsurance for anti-obesity GLP-1 drugs at network retail and by mail, with no dollar cap stated. GEHA Standard lists no separate rate: its regular tiers are 40% up to $350 for a preferred drug and 60% up to $550 for a non-preferred drug for a 30-day supply. Both options require prior authorization and participation in GEHA's weight-management program.
What does FEP Blue charge for Wegovy in 2027?
FEP Blue Standard and Basic have no special rate for obesity drugs. With prior approval, you pay your drug's tier rate at a preferred retail pharmacy: 30% (Tier 2) or 50% (Tier 3) on Standard, and 35% capped at $175 for a 30-day supply (Tier 2) or 60% (Tier 3) on Basic, when Medicare Part B is not primary. The brochure does not say which tier Wegovy is on. The formulary does.
How much is Zepbound if I pay cash?
On November 22, 2026, Lilly's published KwikPen self-pay price was $299 a month for 2.5 mg and $399 for 5 mg. Higher doses were $449 a month if you bought each refill within 45 days. If you miss that window, the regular price is $499 for 7.5 mg and $699 for 10 mg and up.
Can I use my HSA to pay the cash price?
IRS Publication 502 counts prescribed drugs as medical expenses, and counts weight-loss treatment when it treats a specific disease diagnosed by a physician, such as obesity. On that reading, HSA money can pay the cash price for a prescribed drug that insurance did not also pay for. The IRS publications do not name Wegovy or Zepbound.
Related Resources
- Is the FEHB GLP-1 cost share really 50% in 2027?: What the reporting says, plan by plan
- FEHB GLP-1 coverage: How plans cover weight-loss drugs
- FEHB Calculator: Premiums by plan and enrollment type